Date,Open,High,Low,Close,Volume,Dividends,Stock Splits,SMA_10,SMA_40,SMA_120,Close_10_%_D,10_40_%_D,40_120_%_D,RSI,earningsGrowth,revenueGrowth,profitMargins,grossMargins,returnOnEquity,debtToEquity,priceToBook,forwardPE,longName,sector,longBusinessSummary
2025-06-26,3.924999952316284,3.924999952316284,3.924999952316284,3.924999952316284,0,0.0,0.0,,,,,,,,,,0.0,0.0,-0.63978,,18.055555,,,,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
2025-06-27,3.799999952316284,3.990000009536743,3.799999952316284,3.9000000953674316,44338,0.0,0.0,,,,,,,0.0,,,0.0,0.0,-0.63978,,18.055555,,,,"Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor primarily targeting the dopamine system for both treatment resistant organic erectile dysfunction and neuropathic pain in Phase 2b clinical trials; IP2018, a monoamine reuptake inhibitor completed Phase 2a for the treatment of psychogenic erectile dysfunction; and IP2016, which is in preclinical development for the treatment of depression and pain. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark."
